RecruitingNCT06607055

Immunity Markers in Intensive Care Patients and Ventilator-associated Pneumonia

Monitoring of Immunity Markers in Intensive Care Patients and Link with Recurrence and Relapse of Ventilator-associated Pneumonia

Sponsor

Centre Hospitalier Intercommunal Aix-Pertuis

Enrollment

40 participants

Start Date

Oct 4, 2023

Study Type

OBSERVATIONAL

Conditions

Pneumonia, Ventilator-Associated

Summary

The goal of this observational study is to show the direct correlation between the occurrence of recurrence of VAP and postagressive immunoparalysis, monitored by HLA-DR rate below litterature-acknowledged threshold, in a well conducted antibiotherapy context, in patient admitted in the Intensive Care Unit. The main questions it aims to answer are: * evaluation of the association between death and persistence of immunoplegia using HLA-DR monitoring * search an association between immunoplegia depth and severity of the initial state of shock * search an association between immunoplegia depth and viral reactivation * compare association of immunoplegia duration and HLA-DR nadir and VAP occurrence Blood samples will be taken from participants to HLA-DR dosage, at the time of inclusion and once a week then.

Eligibility

Min Age: 18 Years

Inclusion Criteria6

Patient over 18 years old
Patient admitted in the Intensive Care Unit of the CHIAP
Patient under mechanical ventilation
Patient with infectious pneumonia
Informed Consent Form (ICF) obtained from the patient or emergency ICF obtained from close relatives
Patient beneficiary of French social security, whatever the regime

Exclusion Criteria14

Patient under 18 years old
Patient with severe neutropenia (neutrophils \< 0.5 G/L)
Patient under immunosuppressive treatment
Use of corticosteroids (intravenous or oral) prior to ICU admission
Use of therapeutic antibodies
Onco-hematological disease (e.g. lymphoma, leukemia...) under treatment or treated in the 5 years prior to inclusion
End of chemotherapy 6 months prior to inclusion
Patients with innate or acquired immune deficiency (e.g., severe combined immunodeficiency, HIV or AIDS, at any stage)
Patients with a decision to limit or discontinue active therapies, at the time of inclusion
Patients with an estimated ICU stay of less than 48 hours
Participation in an interventional study
Patient deprived of their liberty
Patient under tutorship or curatorship
Pregnant or breastfeeding woman